GSK’s $10.6B Nuvalent Buy: A Bold Reversal or Overpriced Gamble?

Posted on by

(SeaPRwire) –   By: Christian Pierce

GSK just dropped its largest deal in a decade. The British pharma giant is buying Boston biotech Nuvalent for $10.6 billion all-cash. Nuvalent stock jumped 39% in early trading. GSK’s London-listed shares fell 3% on the news. This is a full reversal of its 2014 strategy, when it swapped oncology for Novartis vaccines.

The offer price is $124 per share, a 40% premium over Monday’s close. GSK gains three non-small cell lung cancer programs. Two lead drugs are under FDA review, with decisions due Sept 18 and Nov 27, 2026. A third HER2 inhibitor is in phase I trials. Net of acquired cash, the deal costs $9.4 billion. Funding comes from debt and existing cash, no credit rating impact. GSK’s 2026 full-year guidance remains unchanged. The deal is expected to close Q3 2026 pending regulatory approval. GSK CEO Luke Miels called the two leads potential best-in-class assets.

The deal offsets dolutegravir’s exclusivity loss between 2028 and 2030. It pairs with GSK’s existing Ris-Rez B7-H3 ADC program. This move will force rival pharma firms to bulk up their lung cancer pipelines. The acquisition sets a new floor for early-stage oncology biotech valuations.

Author bio: Christian Pierce, chief financial columnist and markets commentator focused on global biotech and pharma trends.